Pharmaceutical composition and application thereof in preparation of compound preparation
By providing a pharmaceutical composition containing a 5α-reductase inhibitor, a potassium ion channel opener and a phosphodiesterase 5 inhibitor, the problem of the lack of three drug compound preparations in the prior art to treat benign prostatic hyperplasia and androgenic hair loss is solved, and significant therapeutic effects and side effects are reduced.
Patent Information
- Application Number
- CN202311777762.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-22
- Publication Date
- 2025-06-24
AI Technical Summary
There is a lack of methods in the prior art to treat urinary tract symptoms or androgenic hair loss caused by benign prostatic hyperplasia, and the concept of combined medication has not been fully explored.
A pharmaceutical composition consisting of a 5α-reductase inhibitor, a potassium ion channel opener and a phosphodiesterase 5 inhibitor is provided for the preparation of compound preparations for the prevention or treatment of androgen-dependent diseases and complications.
Through the use of this pharmaceutical composition, the urinary tract symptoms of benign prostatic hyperplasia can be significantly improved, the prostate volume can be reduced, the urine flow rate can be increased, the drug use amount can be reduced, the side effects can be reduced, and the patient's compliance can be improved.
Smart Images

Figure BDA0004622828130000021 
Figure BDA0004622828130000111 
Figure BDA0004622828130000112
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceuticals, and particularly relates to a pharmaceutical composition and its application in preparing a compound preparation. Background Art
[0002] Benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA) are both androgen-dependent diseases [1] .
[0003] Benign prostatic hyperplasia (BPH) is a common disease in middle-aged and elderly men. Normal-functioning testes and age are clear factors in its occurrence and development. The onset of BPH is caused by multiple factors, such as: metabolic syndrome, hypertension, hyperlipidemia, diabetes, obesity, vascular lesions, lifestyle, prostatitis, sex hormones and estrogen, apoptosis and growth factors [2] . First, the testes are the main source of androgens in the prostate. The action of androgens is a necessary condition for the occurrence and development of BPH. Androgens bind to the corresponding receptors on prostate cells, causing a disorder in the proliferation and apoptosis of prostate cells by inhibiting apoptosis and promoting cell proliferation, and then leading to prostate hyperplasia [3] . In addition, androgens acting on prostate cells can be converted into dihydrotestosterone (DHT) through the catalytic action of 5α-reductase, and then transformed into estradiol through aromatization. DHT is the most potent androgen in the human body, with an activity 2-3 times that of testosterone and a binding amount to androgen receptors 4-5 times that of testosterone, further promoting prostate hyperplasia.
[0004] There is a certain relationship between the pathophysiology of BPH and lower urinary tract symptoms caused by hypertension [4] . The prior art discloses that for BPH patients with combined hypertension, taking 4 mg of doxazosin (a hypertension drug) orally every day can not only significantly improve prostate obstruction symptoms, but also well control blood pressure levels, indirectly reflecting a certain correlation between hypertension and the development of the BPH course [5] . In addition, phosphodiesterase 5 (PDE5) inhibitor drugs (including sildenafil, tadalafil, vardenafil, etc.) are also disclosed in the prior art to be used alone or in combination with α-blockers to improve the symptoms of patients with moderate to severe lower urinary tract symptoms (LUTS).
[0005] Androgenetic alopecia (AGA) is the most common hair loss disorder, also known as premature alopecia, common baldness or seborrheic alopecia. In most studies, it is believed that androgens play an important role in its pathogenesis. Under the action of androgens, hair follicle dermal papilla cells secrete various cytokines, inducing premature termination of the hair follicle growth phase and resulting in hair loss. Therefore, in view of the above situation, the current drugs for treating AGA are mainly divided into two types: 5α-reductase inhibitors and vasodilators. The representative drug of 5α-reductase inhibitors is finasteride, which can inhibit 5α-reductase and reduce the levels of androgen-dihydrotestosterone (DHT) in serum and scalp. The representative drug of vasodilators is minoxidil, which can increase the mitosis of keratinocytes in the hair matrix, promote hair growth and increase hair diameter. It can also prolong the hair follicle growth phase and stimulate the hair follicle to initiate a new growth cycle.
[0006] Chinese Patent with Publication No. CN101590046A discloses a pharmaceutical composition containing amlodipine, finasteride and a pharmaceutically acceptable carrier, as well as the use of the pharmaceutical composition in the preparation of drugs for treating diseases related to benign prostatic hyperplasia. Through the implementation of this invention, the pharmaceutical composition for a specific use provided to patients not only has a definite curative effect, but also can improve patient compliance, make it convenient for patients to take medicine, reduce medical costs, and has good market prospects. The compound preparation containing two drugs in this invention: amlodipine regulates blood pressure, and finasteride, as a 5α-reductase inhibitor, reduces the concentration of dihydrotestosterone in blood and prostate, significantly reduces the prostate volume, increases the urinary flow rate, and improves clinical symptoms.
[0007] The prior art also discloses Entadfi capsules (finasteride and tadalafil), which are used to treat urinary symptoms caused by benign prostatic hyperplasia (BPH). One capsule is taken orally each time, and the disclosed indication is the initial treatment for up to the signs and symptoms of benign prostatic hyperplasia with prostate enlargement in male patients, and the treatment cycle can be up to 26 weeks at most.
[0008] The relevant drug combination preparations disclosed in the prior art are summarized as follows:
[0009]
[0010] In the prior art, there has been no discovery of using a three-drug compound preparation to treat urinary symptoms caused by benign prostatic hyperplasia or androgenetic alopecia in clinical and preclinical studies. In the current progress of drug treatment, the concept of combination therapy has begun to be advocated, and further development of combination therapy methods is an issue yet to be solved.
[0011] References:
[0012] [1] Xiaoning Yan. High incidence of androgenetic alopecia in men with prostate hyperplasia [J]. World Core Medical Journals Abstracts (Dermatology), 2005(05): 6 - 7.
[0013] [2] Yi Ren, Yao Wang, Ruwen Zheng. Current research status on the etiology and pathogenesis of benign prostatic hyperplasia [J]. World Chinese Medicine, 2018, 13(09): 2372 - 2376.
[0014] [3] Yadav N, Heemers H V, et al. Androgen action in the prostate gland [J]. The Italian journal of urology and nephrology, 2012, 64(1): 35 - 49.
[0015] [4] Hwang EC, Kim SO, Nam DH, et al. Men with Hypertension are More Likely to Have Severe Lower Urinary Tract Symptoms and Large Prostate Volume [J]. Low Urin Tract Symptoms, 2015, 7(1): 32 - 36.
[0016] [5] Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia [J]. J Clin Endocrinol Metab, 2006, 91(7): 2562 - 2568. Summary of the Invention
[0017] To solve the above problems, the present invention provides a compound preparation comprising three types of drugs. Through the implementation of the present invention, the pharmaceutical composition for a specific use not only has definite curative effects, but also can improve patient compliance, make it convenient for patients to take medicine, reduce the drug usage amount, improve the clinical effect and reduce side effects at the same time.
[0018] On the one hand, the present invention provides a pharmaceutical composition.
[0019] The said pharmaceutical composition is composed of a 5α - reductase inhibitor, a potassium ion channel opener and a phosphodiesterase 5 inhibitor.
[0020] Preferably, the content of the 5α-reductase inhibitor is 0.1 - 5 mg, the content of the potassium channel opener is 1 - 100 mg, and the content of the phosphodiesterase 5 inhibitor is 0.1 - 100 mg.
[0021] In the actual application of the drug content involved in the present invention, sometimes it can be understood as the single-dose administration.
[0022] Preferably:
[0023] The 5α-reductase inhibitor includes but is not limited to any one or more of finasteride, dutasteride, and epoprostenol. As a representative drug, finasteride is a 5α-reductase inhibitor. 5α-reductase can metabolize testosterone into dihydrotestosterone in cells, and benign prostatic hyperplasia is caused by the conversion of testosterone into dihydrotestosterone in the prostate. Therefore, finasteride can reduce the concentration of dihydrotestosterone in the blood and prostate by inhibiting 5α-reductase, significantly reduce the volume of the prostate, increase the urinary flow rate, and improve clinical symptoms.
[0024] The potassium channel opener includes but is not limited to any one or more of nicorandil, minoxidil, and fosinopril sodium. As a representative drug, minoxidil can activate ATP-sensitive K+ channels, thereby promoting the outward flow of K+ in smooth muscle cells, causing hyperpolarization of the cell membrane, relaxation of smooth muscle cells, and vasodilation, with a very strong antihypertensive effect. Minoxidil mainly dilates small arteries, and the cardiac output increases due to the reflex increase in myocardial contractility and heart rate. Minoxidil is a very strong renal vasodilator, which can increase renal blood flow, but occasionally the renal blood flow may decrease due to a significant drop in blood pressure, and it also has a very strong effect of stimulating renin secretion. Currently, studies have found that long-term use of minoxidil can also exacerbate the degree of myocardial hypertrophy in hypertensive animals and shorten the survival period.
[0025] The phosphodiesterase 5 (PDE5) inhibitor includes but is not limited to any one or more of tadalafil, sildenafil citrate, udenafil citrate, or vardenafil hydrochloride. As a representative drug, tadalafil is used to treat erectile dysfunction (ED). It treats the symptoms and signs of erectile dysfunction (ED) combined with benign prostatic hyperplasia (BPH).
[0026] More preferably:
[0027] The content of finasteride is 1 - 5 mg, the content of dutasteride is 0.1 - 1 mg, and the content of epoprostenol is 0.1 - 5 mg;
[0028] The content of nicorandil is 1-15 mg, the content of minoxidil is 1-100 mg, and the content of fosinopril sodium is 1-40 mg;
[0029] The content of tadalafil is 0.1-20 mg, the content of sildenafil citrate calculated as sildenafil is 1-100 mg, the content of udenafil citrate calculated as udenafil is 10-100 mg, and the content of vardenafil hydrochloride calculated as vardenafil is 1-20 mg.
[0030] Furthermore:
[0031] The content of finasteride is 1 mg, the content of dutasteride is 0.5 mg, and the content of epoprostenol is 1.5 mg;
[0032] The content of nicorandil is 5 mg, the content of minoxidil is 2.5-40 mg, and the content of fosinopril sodium is 10 mg;
[0033] The content of tadalafil is 2.5-20 mg, the content of sildenafil citrate calculated as sildenafil is 50-100 mg, the content of udenafil citrate calculated as udenafil is 30 mg, and the content of vardenafil hydrochloride calculated as vardenafil is 5-20 mg.
[0034] In some embodiments, the content of minoxidil is 2.5 mg; the content of tadalafil is 2.5 mg, the content of sildenafil citrate calculated as sildenafil is 50 mg, and the content of vardenafil hydrochloride calculated as vardenafil is 5 mg.
[0035] As a preferred embodiment, the 5α-reductase inhibitor is finasteride, the potassium channel opener is minoxidil, and the phosphodiesterase 5 inhibitor is tadalafil.
[0036] Based on the foregoing pharmaceutical composition, the present invention also provides:
[0037] The use of the pharmaceutical composition in the preparation of a compound preparation and the corresponding compound preparation.
[0038] The drug can be used for preventing or treating androgen-dependent diseases or complications of androgen-dependent diseases.
[0039] Specifically, the drug can be used for preventing or treating prostate hyperplasia and / or androgenetic alopecia and complications.
[0040] The compound preparation includes the foregoing pharmaceutical composition as an active ingredient.
[0041] According to the general understanding of those skilled in the art, the compound preparation may further include pharmaceutical excipients. In the present invention, pharmaceutical excipients have the same meaning as pharmaceutically acceptable excipients.
[0042] The pharmaceutical excipients include, but are not limited to, any one or more of buffering agents, excipients, stabilizers, preservatives, controlled release agents, cross-linking agents, and flavoring agents.
[0043] As an example, the pharmaceutical excipients may include any one or more of corn starch, microcrystalline cellulose, lactose, silicon dioxide, magnesium stearate, sodium docusate, pregelatinized starch, sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose sodium, and sodium lauryl sulfate.
[0044] The pharmaceutical dosage form of the compound preparation can be selected according to the routine in the art: including but not limited to tablets, powders, pills, ointments, oral liquids, capsules, syrups, and granules.
[0045] According to the general understanding of those skilled in the art, the pharmaceutical dosage form of the compound preparation can be selected from: ordinary tablets, double-layer tablets, multi-layer tablets, pills, delayed release tablets, timed or site-specific release tablets (timed / site-sustained release tablets), ordinary capsules, sustained release capsules, controlled release capsules, capsules containing pellets or small tablets, pH-dependent capsules containing pellets or small tablets, granules, oral liquids, film agents, or patches, etc.
[0046] Preferably, the compound preparation is an oral dosage form. However, this does not mean that the present invention only protects oral dosage forms. The present invention aims to protect the synergistic effects of different types of drugs and does not limit the actual application form. Therefore, as long as the pharmaceutical dosage form acts through the principle described in the present invention, it is actually within the protection scope of the present invention, including dosage forms that have been disclosed or not disclosed in the prior art.
[0047] As a specific example, the pharmaceutical dosage form of the compound preparation can be a multi-layer tablet.
[0048] In some embodiments, the pharmaceutical dosage form of the compound preparation is a double-layer or triple-layer tablet, selected from any of the following:
[0049] (1) Minoxidil, finasteride, and tadalafil are granulated with excipients respectively and then made into a triple-layer tablet;
[0050] (2) Minoxidil, finasteride, and tadalafil are granulated with excipients respectively, and any two of them are used together as one layer and made into a double-layer tablet with the third drug.
[0051] The minoxidil, finasteride, and tadalafil can be granulated with the same excipients respectively, or can be granulated with different excipients respectively.
[0052] The described granulation method includes, but is not limited to, wet granulation. In fact, those skilled in the art can adjust the granulation method according to the actual situation as long as the drug composition is not affected.
[0053] The combination of the three in the pharmaceutical composition of the present invention can promote the treatment of androgen-dependent diseases or the prevention of complications.
[0054] Specifically, the mechanism of action of the pharmaceutical composition of the present invention for benign prostatic hyperplasia (BPH) is as follows:
[0055] First step, the 5α-reductase inhibitor reduces the concentration of dihydrotestosterone in the blood and prostate, significantly reducing the prostate volume, increasing the urinary flow rate, and improving the clinical symptoms.
[0056] Second step, it can activate the ATP-sensitive K + channel, thereby promoting the K + efflux of smooth muscle cells, causing cell membrane hyperpolarization, smooth muscle cell relaxation, blood vessel dilation, and blood pressure reduction.
[0057] Third step, use phosphodiesterase 5 (Phosphodiesterase5, PDE5) inhibitor drugs to improve moderate to severe lower urinary tract symptoms.
[0058] Specifically, the urinary tract symptoms caused by benign prostatic hyperplasia (BPH) can be blocked multiple times. The synergistic effect of the composition is enhanced compared to single drugs, and the drug resistance is reduced.
[0059] Specifically, the mechanism of action of the pharmaceutical composition of the present invention for androgenetic alopecia (AGA) is as follows:
[0060] On the premise of ensuring the therapeutic effects of 5α-reductase inhibitor drugs (such as finasteride) and vasodilator drugs (such as minoxidil) on AGA, phosphodiesterase 5 (such as tadalafil) is introduced into the prescription to reduce the side effects during the treatment process. Thereby improving patient compliance, making it convenient for patients to take medicine, and reducing the drug usage.
[0061] The therapeutic targets of 5α-reductase inhibitor drugs and vasodilator drugs for AGA are inconsistent, and the two can be used in combination to improve the therapeutic effect. For example, as mentioned in patent CN104755075, a polymer nanoparticle of minoxidil and finasteride locally applied for the treatment of alopecia has pharmacological research results showing that the hair growth and recovery rate are significantly better than single-agent preparations.
[0062] The beneficial effects of the present invention:
[0063] The present invention provides a new pharmaceutical composition by combining a 5α-reductase inhibitor, a potassium channel opener, and a phosphodiesterase 5 inhibitor, which can synergistically promote the treatment of androgen-dependent diseases or the prevention of complications. Taking the drug combination of minoxidil, finasteride, and tadalafil as an example, the present invention verifies the effects in a BPH rat model and an androgenetic alopecia mouse model, indicating a synergistic effect among the three, and develops a new compound preparation with good clinical application prospects. Detailed implementation manners
[0064] The following is a further detailed elaboration of the present invention in combination with specific embodiments. The following embodiments are not used to limit the present invention, but only to illustrate the present invention. The experimental methods used in the following embodiments, unless otherwise specified, and the experimental methods without specific conditions noted in the embodiments are generally in accordance with conventional conditions. The materials, reagents, etc. used in the following embodiments, unless otherwise specified, can be obtained from commercial channels.
[0065] Example 1 Three-layer tablets containing the pharmaceutical composition as the active ingredient
[0066] In the following examples,
[0067] Finasteride was purchased from Hubei Gedian Humanwell Pharmaceutical Co., Ltd., with the product number NFTD210401;
[0068] Minoxidil was purchased from Flamma S.p.A., with the product number 0020002063;
[0069] Tadalafil was purchased from Jiangsu Genor Pharmaceutical Co., Ltd., with the product number 220809A.
[0070] The three-layer tablets in this example include an upper layer, a middle layer, and a lower layer. Specifically:
[0071] Upper layer components (compressed from granule A):
[0072] Name mg / tablet %(w / w) Minoxidil 2.5 2.21 Corn Starch 10 8.83 Microcrystalline Cellulose 20 17.67 Lactose 80 70.67 Silica 0.5 0.44 Magnesium Stearate 0.2 0.18 Total Weight 113.2 100.00
[0073] Granule A was prepared by wet granulation using the aqueous granulation method from the above mixture (except magnesium stearate and silicon dioxide). Subsequently, the granules were dried in a fluidized bed at 50°C, sieved through a screen mesh at 800 rpm for dry sizing, and then lubricated by mixing the remaining components.
[0074] The middle layer (compressed from granule B) contains finasteride, and the components are as follows:
[0075] Name mg / tablet %(w / w) Finasteride 5 5.32 Docusate Sodium 0.35 0.37 Lactose 80 85.11 Microcrystalline Cellulose 3 3.19 Pregelatinized Starch 3 3.19 Sodium Carboxymethyl Starch 2.5 2.66 Magnesium Stearate 0.15 0.16 Total Weight 94 100
[0076] Granule B was granulated from the above mixture (except magnesium stearate) with an aqueous solution containing 0.4% sodium docusate, and then the granule was dried in a fluidized bed at 50 °C and sized through a screen at 800 rpm for dry comminution, and then lubricated by mixing the remaining components.
[0077] The lower layer (compressed granule C) contains tadalafil, and the components are as follows:
[0078] Name mg / tablet %(w / w) Tadalafil 2.5 2.00 Lactose 79.395 63.52 Spray Dried Lactose 12.5 10.00 Hydroxypropyl Cellulose 2 1.60 Croscarmellose Sodium 4.5 3.60 Hydroxypropyl Cellulose (EF) 0.875 0.70 Sodium Lauryl Sulfate 0.35 0.28 Microcrystalline Cellulose 102 18.75 15.00 Croscarmellose Sodium 3.5 2.80 Magnesium Stearate (vegetable) 0.63 0.50 Total Weight 125 100.00
[0079] It was granulated from the above mixture (except microcrystalline cellulose 102, croscarmellose sodium and magnesium stearate) by the aqueous granulation method, and then the granule was dried in a fluidized bed at 50 °C and sized through a screen at 800 rpm for dry comminution, and then lubricated by mixing the remaining components.
[0080] It should be noted that the "upper layer", "middle layer" and "lower layer" in the present invention are referential terms selected for facilitating the distinction of the relative positions of the three components. Those skilled in the art should understand that the "upper layer" and "lower layer" in the present invention actually refer to the two outer layers of the three-layer tablet, and the "middle layer" refers to the sandwich layer between the two outer layers. Those skilled in the art should also know that the terms "upper layer" and "lower layer" can sometimes be interchanged, and after the interchange, the actually prepared product has the same meaning.
[0081] The following Examples 2-8 were prepared with reference to the formulation of Example 1:
[0082] Example 2 Double-layer Tablet
[0083] A double-layer tablet was prepared using the indicated granule A as the first layer and a combination of granule B and granule C as the second layer.
[0084] Comparative Example 1 Minoxidil Tablet
[0085] Granule A was taken for tabletting.
[0086] Comparative Example 2 Finasteride Tablet
[0087] Granule B was taken for tabletting.
[0088] Comparative Example 3 Tadalafil Tablet
[0089] Granule C was taken for tabletting.
[0090] Comparative Example 4 Compound Finasteride Tadalafil Tablet
[0091] Granule B and granule C were compressed into a double-layer tablet.
[0092] Comparative Example 5 Compound Finasteride Minoxidil Tablet
[0093] Granule A and granule B were compressed into a double-layer tablet.
[0094] Comparative Example 6 Compound Tadalafil Minoxidil Tablets
[0095] Granule A and Granule C were compressed into a bilayer tablet.
[0096] Effect of the Pharmaceutical Composition on Rats with BPH Model in Experimental Example 1
[0097] (1) Model Establishment
[0098] Animals: Male Wistar rats, weighing 289±30 g.
[0099] Animal grouping: Divided into 9 groups, namely the blank group (sham operation group), the model group, positive control groups 1-6, and the drug treatment group. 20 rats in each group were used for the experiment, and data elimination may occur in the actual result data.
[0100] Except for the blank group, rats in other groups were intraperitoneally injected with 3.5% chloral hydrate at 350 mg / kg. After anesthesia, bilateral testes were removed (castrated) under sterile conditions, and penicillin was intramuscularly injected at 20,000 U / kg body weight for 3 consecutive days. One week after the castration surgery, subcutaneous injection of testosterone propionate dissolved in olive oil at 0.5 mg / rat was started, once a day for 4 consecutive weeks. At the same time of subcutaneous injection of testosterone propionate in each administration group, intragastric administration was carried out at 1 mL / 100 g body weight, once a day for 4 consecutive weeks; the blank group was intragastrically administered with an equal volume of normal saline.
[0101] (2) Administration
[0102] Blank group; The blank group was intragastrically administered with an equal volume of normal saline, once a day for 4 consecutive weeks;
[0103] Model group (hyperplasia model group): Intragastrically administered with an equal volume of normal saline, once a day for 4 consecutive weeks;
[0104] Positive control group 1: Intragastrically administered with 2.5 mg / kg minoxidil, once a day for 4 consecutive weeks;
[0105] Positive control group 2: Intragastrically administered with 1.0 mg / kg finasteride, once a day for 4 consecutive weeks;
[0106] Positive control group 3: Intragastrically administered with 2.5 mg / kg tadalafil, once a day for 4 consecutive weeks;
[0107] Positive control group 4: Intragastrically administered with 1.0 mg / kg finasteride and 2.5 mg / kg tadalafil, once a day for 4 consecutive weeks;
[0108] Positive control group 5: Intragastrically administered with 1.0 mg / kg finasteride and 2.5 mg / kg minoxidil, once a day for 4 consecutive weeks;
[0109] Positive control group 6: By gavage, 2.5 mg / kg minoxidil and 2.5 mg / kg tadalafil, once a day for four consecutive weeks;
[0110] Drug treatment group: By gavage, the compound tablet of minoxidil, finasteride and tadalafil of the present invention, with a concentration of 2.5 mg / kg minoxidil, 1.0 mg / kg finasteride and 2.5 mg / kg tadalafil, once a day for four consecutive weeks.
[0111] After the administration was completed, the intravesical pressure, body weight, wet weight of the prostate and prostate index of rats in each group were measured.
[0112] Method for measuring urodynamic parameters and urine volume of rats
[0113] Fifteen hours after the last administration of rats in each group, they were anesthetized by intraperitoneal injection of 20% urethane (1 g / kg). A longitudinal incision was made above the pubic arch to expose the bladder. A small hole was punctured at the top of the bladder, and an inner and outer cannula catheter was inserted. One catheter (outer cannula, diameter 1.2 mm) was connected to the Pc-lab multi-channel physiological recording system through a pressure sensor, and the other catheter (inner cannula, diameter 0.61 mm) was connected to a constant rate infusion pump and normal saline was infused at a constant rate. The infusion rate was 2 mL / h. After the rats were stable for 0.5 hours, the urodynamic parameters (voiding point pressure (KPa) and voiding threshold pressure (KPa)) and indicators such as single voiding volume were recorded respectively.
[0114] Determination of prostate index of rats
[0115] After the urine volume measurement was completed, the ventral lobe, coagulating gland and dorsal lobe of the prostate were removed respectively, and the wet weights were weighed. After combining the total weights, the prostate index was calculated according to the following formula: Prostate index = prostate wet weight (mg) / body weight (g).
[0116] (3) Experimental results
[0117] 1) Effects on the intravesical pressure of rats, and the results are shown in Table 1.
[0118] Table 1 Effects of each group on the intravesical pressure of rats
[0119]
[0120] The results in Table 1 show that the micturition point pressure, peak micturition pressure, and bladder volume of rats in the drug treatment group are significantly better than those in the control group, indicating that the compound preparation of the present invention has a significantly better effect on relaxing the smooth muscle of the bladder neck than a single drug or a combination of two of them. Therefore, the compound preparation of the present invention has a significant therapeutic effect. Specifically, Positive Control Group 1 (minoxidil alone) did not show a therapeutic effect on the rat model, Positive Control Group 4 (finasteride and tadalafil in combination) showed a certain therapeutic effect, while the drug treatment group (triple drug combination) further improved the therapeutic effect, indicating that in the present invention, at least minoxidil promoted the efficacy of the combination of finasteride and tadalafil through a synergistic effect, with unexpected technical effects.
[0121] 2) The results of the effects on the body weight, wet prostate weight, and prostate index (PI) of BPH model rats are shown in Table 2.
[0122] Table 2 Effects of the composition on the body weight, wet prostate weight, and prostate index of BPH model rats
[0123]
[0124]
[0125] The results in Table 2 show that in the drug treatment group, after modeling the effects on the body weight, wet prostate weight, and prostate index of BPH model rats, there was no significant difference in the body weight of rats in each group. Compared with the blank group, the wet prostate weight and prostate index of the model group rats were significantly increased, indicating that the BPH model was successfully established. Minoxidil alone had no obvious effect on the wet prostate weight; tadalafil and finasteride alone could significantly reduce the prostate volume and prostate index, and the therapeutic effect of the compound preparation of the two drugs was slightly better than that of the single drug. The combination of the three drugs could significantly reduce the prostate volume and prostate index, and the effect was more significant than that of the single drug group and the two-drug group.
[0126] Experimental Example 2 In vivo pharmacodynamic study of the drug composition for anti-androgenic alopecia
[0127] (1) Animals: Male C57BL / 6 mice, 6 weeks old.
[0128] (2) Experimental method:
[0129] First, the animals were acclimated to the new environment for one week. On Day-1 of the experiment (one day before drug administration), they were anesthetized by intraperitoneal injection of avertin solution. After shaving the hair on the back of the mice with an electric razor, depilatory cream was applied for hair removal. After all the mice had their hair removed, they were randomly divided into groups, with 20 mice in each group. Starting from Day1 (the day of drug administration), the model group was subcutaneously injected with a modeling agent (1 mg testosterone, suspended in a solvent: 10% polysorbate 80 solution), and the modeling agent was injected 4 times every seven days. The corresponding drugs were gavaged to the positive control groups. The drug treatment group was gavaged with the corresponding drugs according to the plan every day.
[0130] (3) Animal grouping, drug administration methods and doses:
[0131] Each group of 20 mice was used for the experiment, and no data were excluded in the actual result data.
[0132] Blank group: gavaged with an equal volume of normal saline once a day for four consecutive weeks;
[0133] Model group: gavaged with an equal volume of normal saline once a day for four consecutive weeks;
[0134] Positive control group 1: gavaged with 2.5 mg / kg minoxidil once a day for four consecutive weeks of drug administration;
[0135] Positive control group 2: gavaged with 1.0 mg / kg finasteride once a day for four consecutive weeks of drug administration;
[0136] Positive control group 3: gavaged with 2.5 mg / kg tadalafil once a day for four consecutive weeks of drug administration;
[0137] Positive control group 4: gavaged with 1.0 mg / kg finasteride and 2.5 mg / kg tadalafil once a day for four consecutive weeks of drug administration;
[0138] Positive control group 5: gavaged with 1.0 mg / kg finasteride and 2.5 mg / kg minoxidil once a day for four consecutive weeks of drug administration;
[0139] Positive control group 6: gavaged with 2.5 mg / kg minoxidil and 2.5 mg / kg tadalafil once a day for four consecutive weeks of drug administration;
[0140] Drug treatment group: gavaged with the compound tablet of minoxidil, finasteride and tadalafil of the present invention, with a concentration of 2.5 mg / kg minoxidil, 1.0 mg / kg finasteride and 2.5 mg / kg tadalafil, once a day for four consecutive weeks of drug administration.
[0141] The animal grouping situation can be seen in Table 3.
[0142] After administration, the hair growth was observed at 1st, 2nd, 3rd, and 4th weeks after administration, and the increased hair number and hair thickness were measured. The hair growth was graded and scored according to the hair growth status (1. short hair; 2. sparse long hair; 3. thick long hair; 4. complete recovery of hair growth).
[0143] Table 3 Animal grouping
[0144]
[0145]
[0146] (4) Experimental results
[0147] The effects of different treatment methods on the hair restoration ability of rats are shown in Table 4.
[0148] Table 4 Comparison of the results of hair restoration ability for different treatment methods
[0149]
[0150]
[0151] The results in Table 4 show that in the drug treatment group, compared with the blank group, the increased hair number and hair thickness of the model group rats did not increase significantly, indicating that the model was successfully established. Finasteride alone had an obvious effect on increasing the hair number and hair thickness. The effects of tadalafil alone or minoxidil alone were similar to those of the blank group, indicating that the two had no significant curative effect on hair growth; the compound preparation of the two drugs had a slightly better treatment effect than the single drug. The combination of the three drugs could significantly increase the hair number and hair thickness, and the effect was more significant than that of the single drug group and the two-drug group.
[0152] The above embodiments are only used to illustrate the present invention and are not used to limit the present invention. Those skilled in the art can make substitutions by conventional means on the basis of the content recorded in the present invention without departing from the spirit of the present invention, such as replacing drug excipients and improving the drug administration form, etc., which are all within the scope of protection of the present invention.
Claims
1. A pharmaceutical composition, characterized in that, It is composed of a 5α-reductase inhibitor, a potassium channel opener, and a phosphodiesterase 5 inhibitor.
2. The pharmaceutical composition according to claim 1, wherein The content of the 5α-reductase inhibitor is 0.1 - 5 mg, the content of the potassium channel opener is 1 - 100 mg, and the content of the phosphodiesterase 5 inhibitor is 0.1 - 100 mg.
3. The pharmaceutical composition according to claim 2, wherein The 5α-reductase inhibitor is selected from: finasteride, dutasteride, epoprostenol; the potassium channel opener is selected from: nicorandil, minoxidil, fosinopril sodium; the phosphodiesterase 5 inhibitor is selected from: tadalafil, sildenafil citrate, udenafil citrate, vardenafil hydrochloride.
4. The pharmaceutical composition according to claim 3, wherein The content of finasteride is 1 - 5 mg, the content of dutasteride is 0.1 - 1 mg, and the content of epoprostenol is 0.1 - 5 mg; The content of nicorandil is 1 - 15 mg, the content of minoxidil is 1 - 100 mg, and the content of fosinopril sodium is 1 - 40 mg; The content of tadalafil is 0.1 - 20 mg, the content of sildenafil citrate calculated as sildenafil is 1 - 100 mg, the content of udenafil citrate calculated as udenafil is 10 - 100 mg, and the content of vardenafil hydrochloride calculated as vardenafil is 1 - 20 mg.
5. The pharmaceutical composition according to claim 4, characterized in that, The content of finasteride is 1 mg, the content of dutasteride is 0.5 mg, and the content of epoprostenol is 1.5 mg; The content of nicorandil is 5 mg, the content of minoxidil is 2.5 - 40 mg, and the content of fosinopril sodium is 10 mg; The content of tadalafil is 2.5 - 20 mg, the content of sildenafil citrate calculated as sildenafil is 50 - 100 mg, the content of udenafil citrate calculated as udenafil is 30 mg, and the content of vardenafil hydrochloride calculated as vardenafil is 5 - 20 mg.
6. The pharmaceutical composition according to claim 5, wherein The content of minoxidil is 2.5 mg; the content of tadalafil is 2.5 mg, the content of sildenafil citrate calculated as sildenafil is 50 mg, and the content of vardenafil hydrochloride calculated as vardenafil is 5 mg.
7. The pharmaceutical composition according to claim 3, wherein The 5α-reductase inhibitor is finasteride, the potassium channel opener is minoxidil, and the phosphodiesterase 5 inhibitor is tadalafil.
8. Use of the pharmaceutical composition according to any one of claims 1 to 7 in the preparation of a compound preparation, characterized in that, The compound preparation is used for preventing or treating androgen-dependent diseases or complications of androgen-dependent diseases.
9. The application according to claim 8, characterized in that, The compound preparation is used for preventing or treating prostate hyperplasia and / or androgenetic alopecia and complications.
10. A compound preparation comprising the pharmaceutical composition according to any one of claims 1 - 7.
11. The compound preparation according to claim 10, wherein It further comprises pharmaceutical excipients, and the pharmaceutical excipients include: any one or more of buffer agents, excipients, stabilizers, preservatives, controlled release agents, crosslinking agents, flavoring agents; preferably, the pharmaceutical excipients include: any one or more of corn starch, microcrystalline cellulose, lactose, silicon dioxide, magnesium stearate, sodium docusate, pregelatinized starch, sodium carboxymethyl starch, hydroxypropyl cellulose, crosslinked carboxymethyl cellulose sodium, sodium lauryl sulfate.
12. The compound preparation according to claim 10, characterized in that, The dosage form of the compound preparation is selected from: ordinary tablets, bilayer tablets, multilayer tablets, pills, delayed-release tablets, timed or site-specific release tablets, ordinary capsules, sustained-release capsules, controlled-release capsules, capsules containing pellets or small tablets, pH-dependent capsules containing pellets or small tablets, granules, oral liquids, films or patches; preferably multilayer tablets; more preferably bilayer or trilayer tablets.
13. The compound preparation according to claim 12, wherein, Selected from any of the following: (1) Minoxidil, finasteride and tadalafil are granulated with excipients respectively and then made into trilayer tablets; (2) Minoxidil, finasteride and tadalafil are granulated with excipients respectively, and any two of them are used together as one layer and made into bilayer tablets with the third drug.
Citation Information
Patent Citations
Medicine combination containing amlodipine besy and finasteride
CN101590046A
Cited By
5alpha-reductase long-acting derivative as well as preparation method and application thereof
CN121108234A
